Literature DB >> 8676450

Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.

M W Pandori1, N J Fitch, H M Craig, D D Richman, C A Spina, J C Guatelli.   

Abstract

Type 1 human immunodeficiency viruses encoding mutated nef reading frames are 10- to 30-fold less infectious than are isogenic viruses in which the nef gene is intact. This defect in infectivity causes nef-negative viruses to grow at an attenuated rate in vitro. To investigate the mechanism of Nef-mediated enhancement of viral growth rate and infectivity, a complementation analysis of nef mutant viruses was performed. To provide Nef in trans upon viral infection, a CEM derivative cell line (designated CLN) that expresses Nef under the control of the viral long terminal repeat was constructed. When nef-negative virus was grown in CLN cells, its growth rate was restored to wild-type levels. However, the output of nef-negative virus during the first 72 h after infection of CLN cells was not restored, suggesting that provision of Nef within the newly infected cell does not enhance the productivity of a nef-negative provirus. The genetically nef-negative virions produced by the CLN cells, however, were restored to wild-type levels of infectivity as measured in a syncytium formation assay in which CD4-expressing HeLa cells were targets. These trans-complemented, genetically nef-negative virions yielded wild-type levels of viral output following a single cycle of replication in primary CD4 T cells as well as in parental CEM cells. To define the determinants for producer cell modification of virions by Nef, the role of myristoylation was investigated. Virus that encodes a myristoylation-negative nef was as impaired in infectivity as was virus encoding a deleted nef gene. Because myristoylation is required for both membrane association of Nef and optimal viral infectivity, the possibility that Nef protein is included in the virion was investigated. Wild-type virions were purified by filtration and exclusion chromatography. A Western blot (immunoblot) of the eluate fractions revealed a correlation between peak Nef signal and peak levels of p24 antigen. Although virion-associated Nef was detected in part as the 27-kDa full-length protein, the majority of immunoreactive protein was detected as a 20-kDa isoform. nef-negative virus lacked both 27- and 20-kDa immunoreactive species. Production of wild-type virions in the presence of a specific inhibitor of the human immunodeficiency virus type 1 protease resulted in virions which contained only 27-kDa full-length Nef protein. These data indicate that Nef is a virion protein which is processed by the viral protease into a 20-kDa isoform within the virion particle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676450      PMCID: PMC190360     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Authors:  H W Kestler; D J Ringler; K Mori; D L Panicali; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

2.  Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes.

Authors:  A de Ronde; B Klaver; W Keulen; L Smit; J Goudsmit
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

3.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo.

Authors:  D C Shugars; M S Smith; D H Glueck; P V Nantermet; F Seillier-Moiseiwitsch; R Swanstrom
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.

Authors:  C Aiken; J Konner; N R Landau; M E Lenburg; D Trono
Journal:  Cell       Date:  1994-03-11       Impact factor: 41.582

6.  Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells.

Authors:  J Kaminchik; N Bashan; A Itach; N Sarver; M Gorecki; A Panet
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

7.  Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene.

Authors:  J Skowronski; D Parks; R Mariani
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

8.  Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection.

Authors:  R E Benson; A Sanfridson; J S Ottinger; C Doyle; B R Cullen
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

9.  The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.

Authors:  M D Miller; M T Warmerdam; I Gaston; W C Greene; M B Feinberg
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes.

Authors:  C A Spina; T J Kwoh; M Y Chowers; J C Guatelli; D D Richman
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  86 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.

Authors:  H Akari; S Arold; T Fukumori; T Okazaki; K Strebel; A Adachi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.

Authors:  E Schaeffer; R Geleziunas; W C Greene
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 5.  Structure--function relationships in HIV-1 Nef.

Authors:  M Geyer; O T Fackler; B M Peterlin
Journal:  EMBO Rep       Date:  2001-07       Impact factor: 8.807

6.  Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.

Authors:  Y Jenkins; P V Sanchez; B E Meyer; M H Malim
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

8.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation.

Authors:  L Alexander; Z Du; M Rosenzweig; J U Jung; R C Desrosiers
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

10.  Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells.

Authors:  Minoru Tobiume; Janet E Lineberger; Christopher A Lundquist; Michael D Miller; Christopher Aiken
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.